Impact of conjugate 7-valent vaccination in Belgium: Addressing methodological challenges

Vaccine

Volumn 29, Issue 16, 2011, Pages 2856-2864

  Hanquet, Germaine ^a,b   Lernout, Tinne ^a,c   Vergison, Anne ^d   Verhaegen, Jan ^e   Kissling, Esther ^a   Tuerlinckx, David ^f   Malfroot, Anne ^g   Swennen, Béatrice ^h   Sabbe, Martine ^a  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b Health Care Knowledge Centre   (Belgium)

^c INSTITUT DE VEILLE SANITAIRE   (France)

^d HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^g UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^h UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Epidemiology; Pneumococcal conjugate vaccine; Surveillance

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; BACTEREMIA; BELGIUM; CHILD; DRUG UPTAKE; HUMAN; MAJOR CLINICAL STUDY; MENINGITIS; MORBIDITY; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIA; TREATMENT OUTCOME; VACCINATION;

BELGIUM; CHILD, PRESCHOOL; HUMANS; IMMUNIZATION SCHEDULE; INCIDENCE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POPULATION SURVEILLANCE; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, CONJUGATE;

EID: 79953211077     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.02.016     Document Type: Article

References (37)

1. Vergison A., Tuerlinckx D., Verhaegen J., Malfroot A. Epidemiologic features of invasive pneumococcal disease in Belgian children: passive surveillance is not enough. Pediatrics 2006, 118(September (3)):e801-e809.
2. Flamaing J., Verhaegen J., Vandeven J., Verbiest N., Peetermans W.E. Pneumococcal bacteraemia in Belgium (1994-2004): the pre-conjugate vaccine era. J Antimicrob Chemother 2008, 61(January (1)):143-149.
3. Robert E., Swennen B. Enquête de couverture vaccinale des enfants de 18 à 24 mois en communauté française (Bruxelles excepté) 2009, ULB, Brussels.
4. Boonen M., Theeten H., Vandermeulen C., Roelants M., Depoorter A., Damme P.V., et al. Vaccinatiegraad bij jonge kinderen en adolescenten in Vlaanderen in 2008. Vlaams Infectieziektebulletin 2009, 68.(November (2)).
5. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348(May (18)):1737-1746.
6. Vestrheim D.F., Lovoll O., Aaberge I.S., Caugant D.A., Hoiby E.A., Bakke H., et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 2008, 26(June (26)):3277-3281.
7. Barricarte A., Castilla J., Gil-Setas A., Torroba L., Navarro-Alonso J.A., Irisarri F., et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study. Clin Infect Dis 2007, 44(June (11)):1436-1441.
8. Dias R., Canica M. Invasive pneumococcal disease in Portugal prior to and after the introduction of pneumococcal heptavalent conjugate vaccine. FEMS Immunol Med Microbiol 2007, 51(October (1)):35-42.
9. Hicks L.A., Harrison L.H., Flannery B., Hadler J.L., Schaffner W., Craig A.S., et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007, 196(November (9)):1346-1354.
10. Lepoutre A., Varon E., Georges S., Gutmann L., Levy-Bruhl D. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. Eur Surveill 2008, 13.(August (35)).
11. Munoz-Almagro C., Jordan I., Gene A., Latorre C., Garcia-Garcia J.J., Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 2008, 46(January (2)):174-182.
12. Singleton R.J., Hennessy T.W., Bulkow L.R., Hammitt L.L., Zulz T., Hurlburt D.A., et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007, 297(April (16)):1784-1792.
13. Cohen R., Levy C., de La Rocque F., Gelbert N., Wollner A., Fritzell B., et al. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr Infect Dis J 2006, 25(November (11)):1001-1007.
14. Huang S.S., Platt R., Rifas-Shiman S.L., Pelton S.I., Goldmann D., Finkelstein J.A. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 2005, 116(September (3)):e408-e413.
15. Hanage W.P. Serotype replacement in invasive pneumococcal disease: where do we go from here?. J Infect Dis 2007, 196(November (9)):1282-1284.
16. Kissling E., Lernout T., Vergison A., Heiden M.V.d., Hanquet G. Capture-recapture analysis comparing two paediatric studies: do we need incentives?. The 2008 European Scientific Conference on Applied Infectious Disease Epidemiology 2008, p. 226.
17. Halloran M.E., Struchiner C.J., Longini I.M. Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol 1997, 146(November (10)):789-803.
18. Ruckinger S., van der Linden M., Reinert R.R., von Kries R., Burckhardt F., Siedler A. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine 2009, 27(June (31)):4136-4141.
19. Rodenburg G.D., de Greeff S.C., Jansen A.G., de Melker H.E., Schouls L.M., Hak E., et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis 2010, 16(May (5)):816-823.
20. Harboe Z.B., Valentiner-Branth P., Benfield T.L., Christensen J.J., Andersen P.H., Howitz M., et al. Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme. Vaccine 2010, 28(March (14)):2642-2647.
21. Fenoll A., Granizo J.J., Aguilar L., Gimenez M.J., Aragoneses-Fenoll L., Hanquet G., et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol 2009, 47(April (4)):1012-1020.
22. Pichon B., Moyce L., Efstratiou A., Slack M., George R. Serotype replacement following the introduction of the PCV7 in the UK-impact on the characteristics of pneumococci causing meningitis. Meningitis Research Foundation's 2009 Conference 2009.
23. Hanquet G., Kissling E., Fenoll A., George R., Lepoutre A., Lernout T., et al. Pneumococcal serotypes in children in 4 European countries. Emerg Infect Dis 2010, 16(September (9)):1428-1439.
24. Konradsen H.B., Kaltoft M.S. Invasive pneumococcal infections in Denmark from 1995 to 1999: epidemiology, serotypes, and resistance. Clin Diagn Lab Immunol 2002, 9(March (2)):358-365.
25. Normark B.H., Ortqvist A., Kalin M., Olsson-Liljequist B., Hedlund J., Svenson S.B., et al. Changes in serotype distribution may hamper efficacy of pneumococcal conjugate vaccines in children. Scand J Infect Dis 2001, 33(11):848-850.
26. Dagan R., Givon-Lavi N., Leibovitz E., Greenberg D., Porat N. Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J Infect Dis 2009, 199(March (6)):776-785.
27. Choi E.H., Kim S.H., Eun B.W., Kim S.J., Kim N.H., Lee J., et al. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis 2008, 14(February (2)):275-281.
28. Van Effelterre T., Moore M.R., Fierens F., Whitney C.G., White L., Pelton S.I., et al. A dynamic model of pneumococcal infection in the United States: implications for prevention through vaccination. Vaccine 2010, 28(May (21)):3650-3660.
29. Moore M.R. Rethinking replacement and resistance. J Infect Dis 2009, 199(March (6)):771-773.
30. Dagan R. Serotype replacement in perspective. Vaccine 2009, 27(August (Suppl. 3)):C22-C24.
31. Amrine-Madsen H., Van Eldere J., Mera R.M., Miller L.A., Poupard J.A., Thomas E.S., et al. Temporal and spatial distribution of clonal complexes of Streptococcus pneumoniae isolates resistant to multiple classes of antibiotics in Belgium, 1997 to 2004. Antimicrob Agents Chemother 2008, 52(September (9)):3216-3220.
32. Goossens H., Ferech M., Vander Stichele R., Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005, 365(February (9459)):579-587.
33. ESAC (European Surveillance of Antimicrobial and Consumption) Antibiotic consumption; online interactive database 2010, ESAC.
34. van de Sande-Bruinsma N., Grundmann H., Verloo D., Tiemersma E., Monen J., Goossens H., et al. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis 2008, 14(November (11)):1722-1730.
35. Goossens H., Coenen S., Costers M., De Corte S., De Sutter A., Gordts B., et al. Achievements of the Belgian Antibiotic Policy Coordination Committee (BAPCOC). Euro Surveill 2008, 13(November (46)).
36. D'Ancona F., Salmaso S., Barale A., Boccia D., Lopalco P.L., Rizzo C., et al. Incidence of vaccine preventable pneumococcal invasive infections and blood culture practices in Italy. Vaccine 2005, 23(March (19)):2494-2500.
37. Ihekweazu C.A., Dance D.A., Pebody R., George R.C., Smith M.D., Waight P., et al. Trends in incidence of pneumococcal disease before introduction of conjugate vaccine: South West England, 1996-2005. Epidemiol Infect 2008, 136(August (8)):1096-1102.